Valuation: Verastem, Inc.

Market Cap 446M 392M 361M 334M 633M 42.74B 646M 4.35B 1.69B 20.92B 1.68B 1.64B 72.61B P/E 2026 *
-3.21x
P/E 2027 * -4.53x
Enterprise Value 281M 247M 228M 211M 399M 26.94B 407M 2.74B 1.06B 13.19B 1.06B 1.03B 45.77B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 1.33x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-0.20%
1 week+13.53%
Current month+33.74%
1 month+33.74%
3 months-8.60%
6 months-34.42%
Current year-33.82%
1 week 4.3
Extreme 4.3
5.17
1 month 3.43
Extreme 3.43
5.17
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
45.78
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Executive Officer

-20,871 0.0339%
22/06Sell

Chief Financial Officer

-4,089 0.0066%
21/05Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+13.53%+6.22%-41.68% 446M
+0.43%-2.69%+72.69%+128.38% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+0.99%+4.54%+20.93%+471.89% 25.26B
+0.32%-3.13%-15.47%-12.05% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
+1.65%+2.51%+40.07%-24.81% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
+1.20%+1.22%+28.27%+196.43% 14.1B
Average +0.73%+6.00%+51.95%+131.09% 23.98B
Weighted average by Cap. +0.32%+2.24%+58.19%+142.70%

Financials

2026 *2027 *
Net sales 102M 89.35M 82.49M 76.23M 144M 9.75B 147M 992M 385M 4.77B 383M 374M 16.57B 178M 156M 144M 133M 253M 17.08B 258M 1.74B 675M 8.36B 670M 655M 29.01B
Net income -167M -146M -135M -125M -236M -15.95B -241M -1.62B -630M -7.8B -625M -612M -27.09B -142M -125M -115M -106M -201M -13.6B -206M -1.38B -537M -6.66B -533M -522M -23.11B
Net Debt -165M -145M -134M -123M -234M -15.8B -239M -1.61B -624M -7.73B -620M -606M -26.84B -210M -184M -170M -157M -297M -20.07B -303M -2.04B -793M -9.82B -787M -770M -34.09B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
09/07/26 USD 5.110 +0.59% 188,291
08/07/26 USD 5.080 +4.74% 4,355,021
07/07/26 USD 4.850 +8.74% 2,851,784
06/07/26 USD 4.460 -0.89% 1,811,512
02/07/26 USD 4.500 +9.76% 2,967,738
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.080USD
Average target price
15.00USD
Spread / Average Target
+195.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock